羅貝考昔

用途

• Acute pain and inflammation associated with musculoskeletal disorders
• Pain and inflammation associated with chronic osteoarthritis (Note: Label likely intended for surgical pain based on injection formulation)
• Perioperative analgesia
• Acute and chronic musculoskeletal pain and inflammation
• Pain and inflammation associated with chronic osteoarthritis
• Pain and inflammation associated with orthopedic or soft tissue surgery
• Perioperative analgesia (orthopaedic and soft tissue surgery)
• Acute and chronic musculoskeletal disorders

給藥方式

可能的副作用

• Decreased appetite
• Vomiting
• Soft feces
• Diarrhea
• Blood in feces (melena/hematochezia)
• Mild gastrointestinal signs (vomiting, soft feces, diarrhea)
• Gastrointestinal ulceration or bleeding (rare but severe)
• Renal toxicity (especially if hypotensive or dehydrated)
• Hepatic accumulation (in patients with pre-existing liver disease)

注意事項與禁忌

• Patients with active gastrointestinal ulcers
• Hypersensitivity to robenacoxib or its excipients
• Dogs with hepatic disease
• Dehydrated, hypovolaemic, or hypotensive patients
• Patients with pre-existing gastrointestinal disease or ulceration
• Patients with blood clotting disorders
• Pregnant or lactating animals
• Dogs < 12 weeks of age or < 2.5 kg body weight
• Cats < 16 weeks of age or < 2.5 kg body weight
• Perioperative use in animals with renal disease (not advisable)
• > **Strict Veterinary Monitoring Required**: Use with extreme caution in patients with impaired cardiac or renal function, dehydration, hypovolemia, hypotension, or in cats with hepatic dysfunction. * **Washout Period**: Do not use concurrently with corticosteroids or other NSAIDs. A treatment-free period of at least 24 hours (accounting for the half-life of the previous drug) should be observed before starting robenacoxib. * **Renal Perfusion**: Use cautiously with drugs that affect renal blood flow (e.g., diuretics, ACE inhibitors) due to the risk of renal toxicity. * **Reproduction**: Safety has not been established in pregnant or lactating animals; use is not recommended.

藥物相互作用

• ACE Inhibitors (e.g., enalapril, benazepril): Some NSAIDs can reduce effects on blood pressure
• Aspirin: May increase the risk of gastrointestinal toxicity (e.g., ulceration, bleeding, vomiting, diarrhea)
• Corticosteroids (e.g., prednisone): May increase the risk of gastrointestinal toxicity (e.g., ulceration, bleeding, vomiting, diarrhea)
• Digoxin: NSAIDs may increase serum levels
• Fluconazole: Administration has increased plasma levels of celecoxib in humans and potentially could also affect robenacoxib levels in dogs
• Furosemide: NSAIDs may reduce the saluretic and diuretic effects
• Highly Protein Bound Drugs (phenytoin, valproic acid, oral anticoagulants, salicylates, sulfonamides, etc.): As robenacoxib is highly bound to plasma proteins (>99%), it may displace other highly bound drugs or be displaced by them, potentially leading to increased serum levels and toxicity
• Methotrexate: Serious toxicity has occurred when NSAIDs have been used concomitantly; use together with extreme caution
• Nephrotoxic Drugs (e.g., aminoglycosides, amphotericin B): May enhance the risk of nephrotoxicity development
• Other NSAIDs: Increased risk of severe gastrointestinal ulceration and renal toxicity. Require a 3-5 day wash-out period.
• Glucocorticoids: Increased risk of severe gastrointestinal ulceration and bleeding.
• Aminoglycosides: Increased risk of nephrotoxicity.

常見問題